sdg9-uhlmann provider logo

Co-Create the Future of Packaging

The immense carbon footprint of the global pharmaceutical and MedTech industry begs for rethinking practices along the entire value chain. Whether it is manufacturing processes, distribution and transport, or the usage and disposal of products - packaging is always the central issue. Innovate and rethink the current processes and practices along the global pharma and MedTech value chain with Uhlmann and “sustainabilize” the future of packaging.  

#responsiblepharma #sustainablevaluechains #sustainablepackaging

  • ✅ Completed
  • 🏁 Winner

    Congratulations to "Clean Filter Packaging" for winning this challenge!

  • 🏆 Prize

    EUR 3,000 per Challenge + funding and collaboration programs + joint publication

  • 🌎 Scope

    International - open to participants from all over the world

Submission Template

For the participation within the Innovate 2030 program, a common submission template is available. This template will help you to structure your ideas and approaches and to find answers to all relevant questions.

The Submission Template is mandatory to submit.

In addition to this submission template, you will find specific requirements and guiding questions for your use case in the "Guiding Questions" section down below.

You can also complement your submission with prototypes, pitch decks, image and video materials, higher-level concepts, or specific use case-related instruments – simply submit these documents along with the submission template via our platform.

Guiding Questions

This Challenge is calling for the most innovative solutions that help co-create the future of packaging in pharma supply chains.

The following guiding questions based on the sub-areas (see tab Important Details) are for your inspiration, and it is not mandatory to answer all of them.

Products, Manufacturing & Packaging:

  1. How can we rethink packaging design to increase pharma supply chain sustainability?
  2. How can integrated cold chain management systems be leveraged?
  3. Which kind of passive, active, or hybrid packaging systems can be exploited and how to increase sustainability?
  4. How can novel smart packaging solutions be used to help drive sustainability efforts forward?
  5. How can volumetric efficiency be improved? How can we avoid access air and space in packaging containers?
  6. How could modular construction approaches to efficient resource use look like in the future?
  7. How could Just-in-time (JIT) manufacturing be exploited to transform packaging supply chains?
  8. Which novel smart packing technologies can be leveraged and how?
  9. Which solutions can meet increasing demands for sustainabilizing cold chain systems?
  10. How could a product’s safety in the supply chain and shelf-life be extended?
  11. How can refurbish, repurpose, and reuse practices be promoted across the supply chain?
  12. Can we rethink and improve products end-of-life strategies?
  13. What kind of reusable packaging and circular business approaches are envisioned for pharma and MedTech use cases?

Pharma Value Chain Systems & Standards

  1. How could novel green distribution systems look like?
  2. How can aviation, truck, ship, and rail logistics system be rethought to increase sustainability in the packaging supply chain?
  3. How and which kind of logistics (e.g., reversed, decentralized) approaches can be leveraged to drive a green revolution?
  4. How can AI software and smart systems “sustainabilize” distribution processes, e.g., by optimizing route synergies to reduce the use of empty containers or the usage of resources to enhance flexibility and efficiency?
  5. Which kind of policies, regulations, and standards are relevant? How can they be answered in 2030?
  6. How can transparency about novel standards and regulations be enabled across the pharma supply chain?
  7. How can adherence to strict safety standards be ensured while still driving the green revolution in pharma and MedTech?
  8. Which smart tracking systems could be leveraged and how?
  9. Which and how can big data insights be leveraged to drive sustainability efforts?
  10. Which kind of partnerships across the supply chain can be initiated and how? Could platform solutions act as an enabler to multi-stakeholder collaboration?
  11. Which collaborations could be developed that enable collection schemes and reprocessing systems?
  12. How could collaborations be developed that combine knowledge and technological expertise to develop scalable solutions?
  13. Which voluntary standards could be thought of that transform sustainable pharma supply chains? How could industry players be brought together to commit to industry-wide voluntary standards? How could they be engaged in data-sharing?

Integrated proposal:

  1. How can we take a holistic view on the supply chain, establishing coordinated and uniform packaging across the entire pharma supply chain?
  2. What kind of system-level approaches can push beyond the quick wins to “sustainabilize” pharma packaging supply chains?
  3. Which proposal can be developed that create a space for collaboration and co-creation to pioneer innovative new digital-first solutions?
  4. How and which approaches or proposal can help future-proof packaging?
  5. Which disruptive elements are worth researching to stay ahead of the curve?
  6. Which novel technologies may become relevant and why?

Criteria & guidelines

Desired Outcome

You can either Deliver: Concrete solutions and prototypes within the more specific sub-areas OR Disrupt: Holistic concepts, strategies, and/or research proposals to co-create the future of pharma packaging supply chains.

Criteria

  • Desirability – What impact does your solution have on users within the pharma/MedTech sector? Why is it desirable (relevant/likeable) to tackle the problem?
  • Feasibility – Why is your approach feasible? How far can you show feasibility? What technical and/or business aspect is yet questionable whether feasible or not?
  • Viability –  What is the impact of your approach on both business within and on the sustainability of the pharma/MedTech sector overall?